The vaccine has been developed by Siberia's Vector Institute, which completed early-stage human trials of the vaccine last week.
Russia registered its first vaccine candidate, developed by Moscow's Gamaleya Institute, in August. Late-stage trials, involving at least 40,000 people, are ongoing.
On Monday it was announced that 156 countries have joined the global COVAX scheme intended to ensure fair distribution of supplies of future vaccines against Covid-19 in an alliance led by the World Health Organization (WHO).
Russia is not listed as participating in the scheme and the Russian vaccine is not listed as being considered for inclusion.
The nine candidate vaccines that are currently being evaluated include two from the US, two from China, two from India, one from South Korea, one from the UK and one global, multi-manufacture partnership. Two of these are in Phase I trials, two are tech transfers and the remainder are at the discovery stage. – Reuters
